Razi Cov Pars
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular, Intranasal
Legal status
Legal status

Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant protein corona vaccine.[1][2][3]It's the second Iranian COVID-19 vaccine reaching human trials[1] and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.[4][5]

Medical uses

It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).[3]

Pharmacology

Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.[2]

Manufacturing

It's planned to produce one million doses of the vaccine each month as of September 2021.[4]

As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.[6]

History

Clinical trials

Clinical trials of Razi Cov Pars
Phase Registration number Start Number of participants Age of participants Ref
Total Vaccine Placebo
I IRCT20201214049709N1 21 January 2021 133 30 (5 µg/200µL)

30 (10 µg/200µL)

30 (20 µg/200µL)

 30 (placebo)

13 (sentinel)

 18-50 years [2]
II IRCT20201214049709N2 13 April 2021 500 18-70 years [3]
III IRCT20201214049709N3 29 August 2021 41,128 20,564 0 (placebo)

20,564 (Sinopharm BIBP vaccine)

 18+ years [5]

See also

References

  1. 1 2 Banihashemi SR, Es-Haghi A, Fallah Mehrabadi MH, Nofeli M, Mokarram AR, Ranjbar A, et al. (2022). "Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models". Frontiers in Immunology. 13: 836745. doi:10.3389/fimmu.2022.836745. PMC 9179012. PMID 35693788.
  2. 1 2 3 "Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial". irct.ir. Iranian Registry of Clinical Trials. Retrieved 21 March 2021.
  3. 1 2 3 "Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial". Iranian Registry of Clinical Trials. Retrieved 22 April 2021.
  4. 1 2 "COVID-19 vaccine Razi Cov Pars starts third clinical trial phase". Tehran Times. 27 August 2021. Retrieved 30 August 2021.
  5. 1 2 "IRCT | Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial". en.irct.ir. Retrieved 30 August 2021.
  6. ↑ "۵ میلیون دز واکسن رازی به وزارت بهداشت تحویل داده شد" [5 million doses of Razi vaccine were delivered to the Ministry of Health]. ایسنا(ISNA) (in Persian). 25 November 2021. Retrieved 27 November 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.